All In MedTech

Device Trial Radar · NCT05941286

Effect of Continuous Glucose Monitoring System Alerts on Diabetes Management in the Hospital

Effect of Continuous Glucose Monitoring System Alerts on Diabetes Management in the Hospital: a Randomised Controlled Trial

Last checked: Nov 20, 2026Latest source record: Dec 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 533 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

533

Actual

Start

Apr 18, 2024

Primary completion

Dec 16, 2024

Study completion Dec 16, 2024

Sponsor

Lead sponsor
Shanghai 6th People's HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 12, 2023

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Current continuous glucose monitoring (CGM) devices provide features that alert for current and impending adverse glycemic events.This trial aims to examine whether these glucose alerts provided added benefit on glycemic outcomes in patients with type 1 or 2 diabetes who required intensive insulin therapy during hospitalization.

Conditions

  • Diabetes Mellitus

Interventions

  • CGM system with both glucose predictive alerts and threshold alerts onDevice

    the cloud-based real-time continuous glucose monitoring and management system with both glucose predictive alerts and threshold alerts on

  • CGM system with only glucose threshold alerts onDevice

    the cloud-based real-time continuous glucose monitoring and management system with only glucose threshold alerts on

  • CGM system with glucose alerts offDevice

    the cloud-based real-time continuous glucose monitoring and management system with glucose predictive/threshold alerts off

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time in range (3.9~10.0mmol/L, %)Time frame: Through study completion (during hospitalization, 5-7 days)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Sixth People's Hospital

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.